DOCSLIB.ORG

Kpco Authorization Guidelines June2020

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Kpco Authorization Guidelines June2020 COLORADO - MEDICATION AUTHORIZATION GUIDELINES CORTICOTROPIN Generic Brand HICL GCN Exception/Other CORTICOTROPIN ACTHAR HP GEL 02830 GUIDELINES FOR USE 1. Does the patient have a contraindication† to Acthar? (See contraindication list at the end of this guideline) If yes, do not approve. If no, continue to #2. 2. Will the Acthar injections be administered in a medical office? If yes, do not approve. This will be a medical benefit. If no, continue to #3. 3. Is the patient less than 2 years old and diagnosed with infantile spasms? If yes, approve for 28 days with a maximum of 8 vials (each 5mL vial contains 400 units). If no, continue to #4. 4. Does the patient have a diagnosis of nephrotic syndrome? If yes, continue to #10. If no, continue to #5. 5. Is the patient being treated for acute exacerbation of multiple sclerosis? If yes, continue to #6. If no, do not approve. 6. Does the patient have a contraindication (documented hypersensitivity) to prednisone, methylprednisolone, and dexamethasone? If yes, approve up to 120 units/day for up to 21 days (each 5mL vial contains 400 units). If no, continue to #7. 7. Has the patient failed a 3-day course of PO prednisone of at least 500mg daily, with or without a short PO prednisone taper afterwards, for this current exacerbation? If yes, continue to #8. If no, do not approve. Effective: June 2020 NOTE: These guidelines are subject to change at any time throughout the year COLORADO - MEDICATION AUTHORIZATION GUIDELINES 8. Has the patient failed a 7-day course of IV or PO dexamethasone of at least 8mg daily, with or without a short PO prednisone or dexamethasone taper afterwards, for this current exacerbation? If yes, continue to #9. If no, do not approve. 9. Has the patient failed a 3-day course of IV methylprednisolone of at least 500mg daily, with or without a short oral prednisone taper afterwards, for this current exacerbation? If yes, approve up to 120 units/day for up to 21 days (each 5mL vial contains 400 units). If no, do not approve. 10. Is this prescribed by a nephrologist? If yes, continue to #11. If no, do not approve. 11. Has the patient previously been approved by Kaiser Permanente Colorado for this medication? If yes, continue to #17. If no, continue to #12. 12. Has the patient failed prednisone or prednisolone due to side effects or failure to achieve sustained partial* or complete** remission of nephrotic syndrome after 6 months of treatment? (See definitions of partial and complete remission at the end of this guideline) If yes, continue to #13. If no, do not approve. 13. Has the patient failed cyclosporine or tacrolimus due to side effects or failure to achieve sustained partial* or complete** remission of nephrotic syndrome after 6 months of treatment? (See definitions of partial and complete remission at the end of this guideline) If yes, continue to #14. If no, do not approve. 14. Has the patient failed mycophenolate mofetil or azathioprine due to side effects or failure to achieve sustained partial* or complete** remission of nephrotic syndrome after 6 months of treatment? (See definitions of partial and complete remission at the end of this guideline) Effective: June 2020 NOTE: These guidelines are subject to change at any time throughout the year COLORADO - MEDICATION AUTHORIZATION GUIDELINES If yes, continue to #15. If no, do not approve. 15. Has the patient failed cyclophosphamide or chlorambucil due to side effects or failure to achieve sustained partial* or complete** remission of nephrotic syndrome after 6 months of treatment? (See definitions of partial and complete remission at the end of this guideline) If yes, continue to #16. If no, do not approve. 16. Has the patient failed rituximab due to side effects or failure to achieve sustained partial* or complete** remission of nephrotic syndrome after 6 months of treatment? (See definitions of partial and complete remission at the end of this guideline) If yes, approve up to 160 units/week for 6 months (each 5mL vial contains 400 units). If no, do not approve. 17. Did the patient achieve sustained partial* or complete** remission of nephrotic syndrome after 6 months of treatment? (See definitions of partial and complete remission at the end of this guideline) If yes, approve up to 160 units/week for 6 months (each 5mL vial contains 400 units). If no, do not approve. *A partial response in patients presenting with nephrotic range proteinuria is a reduction of ≥50 percent (either protein:cr or albumin:cr ratio), and to less than 3.5 g/day confirmed by 2 values at least 2 weeks apart AND accompanied by an improvement in creatinine (value less than before treatment started). **A complete response is a reduction in proteinuria to <200 to 300 mg/day (either protein:cr or albumin:cr ratio) confirmed by 2 values at least 2 weeks apart and accompanied with a normal creatinine (<1.1). †Contraindications to Acthar A. concomitant use of live or live attenuated vaccines when receiving immunosuppressive corticotropin dose (also a contraindication to prednisone and methylprednisolone) B. congenital infection in infants C. congestive heart failure D. hypertension, uncontrolled E. intravenous administration F. ocular herpes simplex infection G. osteoporosis Effective: June 2020 NOTE: These guidelines are subject to change at any time throughout the year COLORADO - MEDICATION AUTHORIZATION GUIDELINES H. peptic ulcers, history or presence of I. primary adrenocortical insufficiency or adrenocortical hyperactivity J. scleroderma K. sensitivity to porcine protein L. surgery, recent M. systemic fungal infection (also a contraindication to prednisone, methylprednisolone and dexamethasone) Creation date: 10/25/2013 Effective date: 11/6/2013 Reviewed date: 7/1/2019 Revised date: 11/1/2016 Effective: June 2020 NOTE: These guidelines are subject to change at any time throughout the year COLORADO - MEDICATION AUTHORIZATION GUIDELINES DROXIDOPA Generic Brand HICL GCN Exception/Other DROXIDOPA NORTHERA 40936 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is this being prescribed by a neurologist or cardiologist? If yes, continue to #2. If no, do not approve. 2. Is the patient 18 years of age or older? If yes, continue to #3. If no, do not approve. 3. Does the patient have a confirmed diagnosis of neurogenic hypotension due to Parkinson’s disease, pure autonomic failure, multisystem atrophy, non-diabetic autonomic neuropathy, or dopamine-β-hydroxylase deficiency? If yes, continue to #4. If no, do not approve. 4. Does the patient have ischemic heart disease, arrhythmias, congestive heart failure, or sustained, severe hypertension (systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg sitting or supine)? If yes, do not approve. If no, continue to #5. 5. Does the patient have aspirin hypersensitivity or a yellow dye allergy? If yes, do not approve. If no, continue to #6. 6. Does the patient have severe renal impairment (CrCl less than 30 mL/min)? If yes, do not approve. If no, continue to #7. 7. Is the patient currently breastfeeding? Effective: June 2020 NOTE: These guidelines are subject to change at any time throughout the year COLORADO - MEDICATION AUTHORIZATION GUIDELINES If yes, do not approve. If no, continue to #8. 8. Is the patient currently utilizing a non-selective MAO inhibitor, linezolid, or tedizolid*? If yes, do not approve. If no, continue to #9. 9. Is the patient symptomatic despite using non-pharmacological interventions (getting up slowly, wearing elastic stockings, adequate salt and fluid intake, elevating the head of the bed, leg-crossing, thigh contraction, etc.)? If yes, continue to #10. If no, do not approve. 10. Has the patient tried and failed fludrocortisone and midodrine individually and as a combination? If yes, approve x3 months, max daily dose #6. If no, do not approve. RENEWAL CRITERIA 1. Has the patient developed symptoms of neuroleptic malignant syndrome; ischemic heart disease; arrhythmias; congestive heart failure; sustained, severe hypertension (systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg sitting or supine); severe renal impairment (CrCl less than 30 mL/min); or has the patient started a non-selective MAO inhibitor, linezolid, tedizolid*, or breast-feeding? If yes, do not approve. If no, continue to #2. 2. Have the patient’s symptoms improved? If yes, approve x6 months, max daily dose #6. If no, do not approve. *Possible theoretical interaction for tedizolid. Creation date: 11/16/2016 Effective date: 1/1/2017 Reviewed date: 7/1/2019 Revised date: 11/1/2016 Effective: June 2020 NOTE: These guidelines are subject to change at any time throughout the year COLORADO - MEDICATION AUTHORIZATION GUIDELINES SOMATROPIN Generic Brand HICL GCN Exception/Other SOMATROPIN GENOTROPIN 02824 HUMATROPE NORDIFLEX NORDITROPIN NUTROPIN NUTROPIN AQ NUTROPIN DEPOT OMNITROPE (FORMULARY) SAIZEN SEROSTIM TEV-TROPIN ZOMACTON ZORBTIVE GUIDELINES FOR USE 1. Is the requested medication for Serostim, prescribed for the treatment of HIV/AIDS- wasting syndrome? If yes, continue to #15. If no, continue to #2. 2. Is the requested medication for Zorbtive, prescribed for the treatment of short-bowel syndrome? If yes, continue to #21. If no, continue to #3. 3. Is the requested medication Omnitrope? If yes, continue to #5. If no, continue to #4. 4. Has the patient tried or does the patient have a contraindication to Omnitrope? If yes, continue to #5. If no, do not approve. 5. Does the patient have a diagnosis of Idiopathic Short Stature (not growth hormone- deficient short stature), or is somatropin being prescribed for athletic enhancement or anti-aging purposes? Effective: June 2020 NOTE: These guidelines are subject to change at any time throughout the year COLORADO - MEDICATION AUTHORIZATION GUIDELINES If yes, do not approve. If no, continue to #6.
Load more

Recommended publications
  • DRUGS REQUIRING PRIOR AUTHORIZATION in the MEDICAL BENEFIT Page 1
    Effective Date: 08/01/2021 DRUGS REQUIRING PRIOR AUTHORIZATION IN THE MEDICAL BENEFIT Page 1 Therapeutic Category Drug Class Trade Name Generic Name HCPCS Procedure Code HCPCS Procedure Code Description Anti-infectives Antiretrovirals, HIV CABENUVA cabotegravir-rilpivirine C9077 Injection, cabotegravir and rilpivirine, 2mg/3mg Antithrombotic Agents von Willebrand Factor-Directed Antibody CABLIVI caplacizumab-yhdp C9047 Injection, caplacizumab-yhdp, 1 mg Cardiology Antilipemic EVKEEZA evinacumab-dgnb C9079 Injection, evinacumab-dgnb, 5 mg Cardiology Hemostatic Agent BERINERT c1 esterase J0597 Injection, C1 esterase inhibitor (human), Berinert, 10 units Cardiology Hemostatic Agent CINRYZE c1 esterase J0598 Injection, C1 esterase inhibitor (human), Cinryze, 10 units Cardiology Hemostatic Agent FIRAZYR icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent HAEGARDA c1 esterase J0599 Injection, C1 esterase inhibitor (human), (Haegarda), 10 units Cardiology Hemostatic Agent ICATIBANT (generic) icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent KALBITOR ecallantide J1290 Injection, ecallantide, 1 mg Cardiology Hemostatic Agent RUCONEST c1 esterase J0596 Injection, C1 esterase inhibitor (recombinant), Ruconest, 10 units Injection, lanadelumab-flyo, 1 mg (code may be used for Medicare when drug administered under Cardiology Hemostatic Agent TAKHZYRO lanadelumab-flyo J0593 direct supervision of a physician, not for use when drug is self-administered) Cardiology Pulmonary Arterial Hypertension EPOPROSTENOL (generic)
    [Show full text]
  • Pharmacokinetics, Pharmacodynamics and Drug
    pharmaceutics Review Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of New Anti-Migraine Drugs—Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies Danuta Szkutnik-Fiedler Department of Clinical Pharmacy and Biopharmacy, Pozna´nUniversity of Medical Sciences, Sw.´ Marii Magdaleny 14 St., 61-861 Pozna´n,Poland; [email protected] Received: 28 October 2020; Accepted: 30 November 2020; Published: 3 December 2020 Abstract: In the last few years, there have been significant advances in migraine management and prevention. Lasmiditan, ubrogepant, rimegepant and monoclonal antibodies (erenumab, fremanezumab, galcanezumab, and eptinezumab) are new drugs that were launched on the US pharmaceutical market; some of them also in Europe. This publication reviews the available worldwide references on the safety of these anti-migraine drugs with a focus on the possible drug–drug (DDI) or drug–food interactions. As is known, bioavailability of a drug and, hence, its pharmacological efficacy depend on its pharmacokinetics and pharmacodynamics, which may be altered by drug interactions. This paper discusses the interactions of gepants and lasmiditan with, i.a., serotonergic drugs, CYP3A4 inhibitors, and inducers or breast cancer resistant protein (BCRP) and P-glycoprotein (P-gp) inhibitors. In the case of monoclonal antibodies, the issue of pharmacodynamic interactions related to the modulation of the immune system functions was addressed. It also focuses on the effect of monoclonal antibodies on expression of class Fc gamma receptors (FcγR). Keywords: migraine; lasmiditan; gepants; monoclonal antibodies; drug–drug interactions 1. Introduction Migraine is a chronic neurological disorder characterized by a repetitive, usually unilateral, pulsating headache with attacks typically lasting from 4 to 72 h.
    [Show full text]
  • Commercial and Medicaid Formulary Changes Effective 1/1/21
    Commercial and Medicaid formulary changes effective 1/1/21 These additions and changes apply to Commercial and Medicaid formularies and are effective 1/1/21 unless specified below. Additions Tecartus™ (brexucabtagene autoleucel) – Medical Benefit, PA Required (Reviewed by Medical Director). Rukobia®(fostemavir) – Non-Preferred Brand, QL Required. Phexxi (lactic acid, citric acid, and potassium bitartrate) – Non-Preferred Brand, QL Required. Viltepso (viltolarsen) – Medical Benefit, PA Required. Dayvigo (lemborexant) – Non-Preferred Brand, PA and QL Required. Barhemsys (amisulpride) – Medical Benefit. Blenrep (belanta mabmafodotin-blmf) – Medical Benefit, PA Required. Monjuvi (tafasitamab-cxix) – Medical Benefit, PA Required. Trijardy (empagliflozin/linagliptin/metformin) – Non-Preferred Brand, Step Therapy Required. Procysbiv (cysteamine) – Non-Preferred Brand, PA Required. Hemadyv (dexamethasone) – Non-Preferred Brand, PA and QL Required. Kynmobi (apomorphine) – Non-Preferred Brand, PA and QL Required. Zerviate (cetirizine) – Non-Preferred Brand, Step Therapy Required. Freestyle Libre 2 – Preferred Brand, PA and QL Required. Changes Belsomra (suvorexant) – Change to Non-Preferred Brand, PA and QL Required. Apokyn (apomorphine SC) – Change to Non-Preferred Brand, PA and QL Required. Copaxone (brand only) – Changed from Tier 3 to Tier 2 (only applies to commercial). Humalog (insulin lispro) – Changed from Tier 3 to Tier 2 (only applies to commercial). Nurtec ODT (rimegepant) – Changed from Tier 4 to Tier 3 (only applies to commercial). Reyvow (lasmiditan) – Change to Non-Preferred Brand, PA and QL Required (only applies to commercial). Ubrelvy (ubrogepant) – Change to Non-Preferred Brand, PA and QL Required (only applies to commercial). Soliqua (insulin glargine-lixisenatide) – Changed from Tier 4 to Tier 3 (only applies to commercial). Prefest (estradiol-norgestimate) – Moved to Non-formulary (only applies to commercial).
    [Show full text]
  • Galcanezumab-Gnlm) Injection, for Subcutaneous Use
    1 HIGHLIGHTS OF PRESCRIBING INFORMATION • Administer in the abdomen, thigh, back of the upper arm, or These highlights do not include all the information needed to use buttocks subcutaneously. (2.3) EMGALITY safely and effectively. See full prescribing information for EMGALITY. ---------------------- DOSAGE FORMS AND STRENGTHS --------------------­ • Injection: 120 mg/mL solution in a single-dose prefilled pen (3) EMGALITY (galcanezumab-gnlm) injection, for subcutaneous use Initial U.S. Approval: 2018 • Injection: 120 mg/mL solution in a single-dose prefilled syringe (3) • Injection: 100 mg/mL solution in a single-dose prefilled syringe (3) --------------------------- RECENT MAJOR CHANGES -------------------------­ Indications and Usage, Episodic Cluster Headache (1.2) 06/2019 ------------------------------- CONTRAINDICATIONS -----------------------------­ Dosage and Administration, Recommended Dosing for Episodic EMGALITY is contraindicated in patients with serious hypersensitivity Cluster Headache (2.2) 06/2019 to galcanezumab-gnlm or to any of the excipients. (4) ---------------------------- INDICATIONS AND USAGE --------------------------­ ------------------------ WARNINGS AND PRECAUTIONS ----------------------­ EMGALITY® is a calcitonin-gene related peptide antagonist indicated in Hypersensitivity Reactions: If a serious hypersensitivity reaction adults for the: occurs, discontinue administration of EMGALITY and initiate appropriate therapy. Hypersensitivity reactions could occur days after • preventive treatment of migraine. (1.1)
    [Show full text]
  • NCT04179474 Study ID: 3110‐108‐002 Title: A
    NCT04179474 Study ID: 3110‐108‐002 Title: A Phase 1b, Two‐Part, Open‐Label, Fixed‐Sequence, Safety, Tolerability and Drug‐Drug Interaction Study Between Single Dose Erenumab or Galcanezumab and Multiple Dose Ubrogepant in Participants with Migraine Protocol Date: 14Aug2019 CONFIDENTIAL Protocol 3110-108-002 Ubrogepant (AGN-241688) Title Page Protocol Title: A Phase 1b, Two-Part, Open-Label, Fixed-Sequence, Safety, Tolerability and Drug-Drug Interaction Study Between Single Dose Erenumab or Galcanezumab and Multiple Dose Ubrogepant in Participants with Migraine Protocol Number: 3110-108-002 Product: Ubrogepant (AGN-241688, MK-1602) Brief Protocol Title: Drug-Drug Interaction Study of Ubrogepant with Erenumab or Galcanezumab Study Phase: 1b Sponsor Name and Legal Registered Address: Allergan Pharmaceuticals International Limited, Clonshaugh Industrial Estate, Coolock, Dublin 17, Ireland US Agent: Allergan Sales, LLC, 2525 Dupont Dr, Irvine, California 92612, USA Regulatory Agency Identifying Number(s): IND #113924 SAE Reporting Fax Number/Email: Business Unit Email Phone Fax Allergan Approval Date: 14 August 2019 1 GRD-CLN-T-01-01 v3.0 CONFIDENTIAL Protocol 3110-108-002 Ubrogepant (AGN-241688) Sponsor Signatories: Date Date The signatures of the sponsor signatories are collected on the protocol approval page. 2 GRD-CLN-T-01-01 v3.0 CONFIDENTIAL Protocol 3110-108-002 Ubrogepant (AGN-241688) Table of Contents Title Page .........................................................................................................................................1
    [Show full text]
  • 761063Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 761063Orig1s000 CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S) Office of Clinical Pharmacology Review BLA Number 761063 Link to EDR \\cdsesub1\evsprod\bla761063\0001\m1\us\cover.pdf Submission Date 10/27/2017 Submission Type NME, Standard Review Brand Name EMGALITYTM Generic Name Galcanezumab Dosage Form and Strength 120 mg/mL Prefilled auto-injector pen and Pre-filled syringe Route of Administration Subcutaneous injection Proposed Dose/Regimen: 120 mg once monthly, with a 240 mg loading dose as the initial dose Proposed Indication preventive treatment of migraine Applicant Eli Lilly and Company Associated IND 111295 OCP Review Team Bilal AbuAsal, Ph.D., Gopichand Gottipati, Ph.D., Kevin Krudys, Ph.D., Sreedharan Sabarinath, Ph.D. OCP Final Signatory Ramana Uppoor, Ph.D. 1 Reference ID: 4278873 Table of Contents 1. EXECUTIVE SUMMARY .......................................................................................................................... 3 1.1 Recommendations ........................................................................................................................ 3 1.2 Post-Marketing Requirements and Commitments ....................................................................... 4 2. SUMMARY OF CLINICAL PHARMACOLOGY ASSESSMENT ..................................................................... 5 2.1 Pharmacology and Clinical Pharmacokinetics............................................................................... 5 2.2 Dosing and
    [Show full text]
  • VYEPTI™ (EPTINEZUMAB) Policy Number: CSLA2020D0090A Effective Date: TBD
    Proprietary Information of United Healthcare: The information contained in this document is proprietary and the sole property of United HealthCare Services, Inc. Unauthorized copying, use and distribution of this information are strictly prohibited. Copyright 2020 United HealthCare Services, Inc. UnitedHealthcare® Community Plan Medical Benefit Drug Policy VYEPTI™ (EPTINEZUMAB) Policy Number: CSLA2020D0090A Effective Date: TBD Table of Contents Page Commercial Policy APPLICATION ...................................................... 1 Vyepti™ (Eptinezumab) COVERAGE RATIONALE ........................................ 1 APPLICABLE CODES ............................................. 2 BACKGROUND ................................................... 43 CLINICAL EVIDENCE ............................................ 4 U.S. FOOD AND DRUG ADMINISTRATION ............ 54 CENTERS FOR MEDICARE AND MEDICAID SERVICES 54 REFERENCES ....................................................... 5 POLICY HISTORY/REVISION INFORMATION ...... 65 INSTRUCTIONS FOR USE .................................... 65 APPLICATION This Medical Benefit Drug Policy only applies to state of Louisiana. COVERAGE RATIONALE Vyepti has been added to the Review at Launch program. Please reference the Medical Benefit Drug Policy titled Review at Launch for New to Market Medications for additional details. Chronic Migraine Vyepti is proven and medically necessary for the preventive treatment of chronic migraines when all of the following criteria are met: For initial therapy, all of the
    [Show full text]
  • Immunfarmakológia Immunfarmakológia
    Gergely: Immunfarmakológia Immunfarmakológia Prof Gergely Péter Az immunpatológiai betegségek döntő többsége gyulladásos, és ennek következtében általában szövetpusztulással járó betegség, melyben – jelenleg – a terápia alapvetően a gyulladás csökkentésére és/vagy megszűntetésére irányul. Vannak kizárólag gyulladásgátló gyógyszereink és vannak olyanok, amelyek az immunreakció(k) bénításával (=immunszuppresszió révén) vagy emellett vezetnek a gyulladás mérsékléséhez. Mind szerkezetileg, mind hatástanilag igen sokféle csoportba oszthatók, az alábbi felosztás elsősorban didaktikus célokat szolgál. 1. Nem-szteroid gyulladásgátlók (‘nonsteroidal antiinflammatory drugs’ NSAID) 2. Kortikoszteroidok 3. Allergia-elleni szerek (antiallergikumok) 4. Sejtoszlás-gátlók (citosztatikumok) 5. Nem citosztatikus hatású immunszuppresszív szerek 6. Egyéb gyulladásgátlók és immunmoduláns szerek 7. Biológiai terápia 1. Nem-szteroid gyulladásgátlók (NSAID) Ezeket a vegyületeket, melyek őse a szalicilsav (jelenleg, mint acetilszalicilsav ‘aszpirin’ használatos), igen kiterjedten alkalmazzák a reumatológiában, az onkológiában és az orvostudomány szinte minden ágában, ahol fájdalom- és lázcsillapításra van szükség. Egyes felmérések szerint a betegek egy ötöde szed valamilyen NSAID készítményt. Szerkezetük alapján a készítményeket több csoportba sorolhatjuk: szalicilátok (pl. acetilszalicilsav) pyrazolidinek (pl. fenilbutazon) ecetsav származékok (pl. indometacin) fenoxiecetsav származékok (pl. diclofenac, aceclofenac)) oxicamok (pl. piroxicam, meloxicam) propionsav
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • A Multicenter, Randomized, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Ubrogepant in Th
    NCT02873221 Study ID: UBR‐MD‐04 Title: A Multicenter, Randomized, Open‐Label Extension Study to Evaluate the Long‐Term Safety and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura Protocol Amd 3 Date: 11‐Apr‐2018 Allergan Confidential Protocol UBR-MD-04 Amendment 3 Title Page ALLERGAN – CONFIDENTIAL The following contains confidential, proprietary information which is the property of Allergan A MULTICENTER, RANDOMIZED, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA Protocol Number: UBR-MD-04 Amendment 3 Phase: 3 Name of Investigational Product: Ubrogepant Sponsor: Allergan Pharmaceuticals Authorized US Agent International Limited Allergan Sales, LLC Clonshaugh Industrial Estate 2525 Dupont Drive Coolock Irvine, California USA 92612 Dublin 17 +1-714-246-4500 Ireland +1-800-347-4500 Emergency Telephone Number(s): Refer to the Study Contacts Page Serious Adverse Event Reporting Fax Number: Allergan Medical Safety Physician Please see Study Contact Sheet Contact Information: Allergan Signatory: Original Protocol Date: 02 May 2016 Protocol Amendment 1 Date: 15 Nov 2016 Protocol Amendment 2 Date: 06 Dec 2017 Protocol Amendment 3 Date: 11 Apr 2018 The following information can be found on FDA Form 1572 and/or study contacts page: Name and contact information of Allergan study personnel and Emergency Telephone Numbers; name, address, and statement of qualifications of each investigator; name of each subinvestigator working under the supervision of the investigator; name and address of the research facilities to be used; name and address of each reviewing IRB; US 21 CFR 312.23 section 6(iii)b.
    [Show full text]
  • Medicines/Pharmaceuticals of Animal Origin V3.0 November 2020
    Medicines/pharmaceuticals of animal origin V3.0 November 2020 Medicines/pharmaceuticals of animal origin - This guideline provides information for all clinical staff within Hospital and Health Services (HHS) on best practice for avoidance of issues related to animal products. Medicines/pharmaceuticals of animal origin - V3.0 November 2020 Published by the State of Queensland (Queensland Health), November 2020 This document is licensed under a Creative Commons Attribution 3.0 Australia licence. To view a copy of this licence, visit creativecommons.org/licenses/by/3.0/au © State of Queensland (Queensland Health) 2020 You are free to copy, communicate and adapt the work, as long as you attribute the State of Queensland (Queensland Health). For more information contact: Medication Services Queensland, Queensland Health, GPO Box 48, Brisbane QLD 4001, email [email protected] An electronic version of this document is available at https://www.health.qld.gov.au/__data/assets/pdf_file/0024/147507/qh-gdl-954.pdf Disclaimer: The content presented in this publication is distributed by the Queensland Government as an information source only. The State of Queensland makes no statements, representations or warranties about the accuracy, completeness or reliability of any information contained in this publication. The State of Queensland disclaims all responsibility and all liability (including without limitation for liability in negligence) for all expenses, losses, damages and costs you might incur as a result of the information being inaccurate
    [Show full text]
  • (CGRP) Inhibitor Criteria – Migraine and Cluster Headache Prevention Approval Date: February 24, 2021
    New Hampshire Medicaid Fee-for-Service Program Calcitonin Gene-Related Peptide (CGRP) Inhibitor Criteria – Migraine and Cluster Headache Prevention Approval Date: February 24, 2021 Medications Brand Names Generic Names Dosage 70 mg/mL solution single-dose prefilled syringe or auto-injector; Aimovig® erenumab-aooe 140 mg/mL prefilled syringe and autoinjector 225 mg/1.5 mL solution single-dose prefilled syringe; Ajovy® fremanezumab-vfrm 225 mg/1.5 mL autoinjector 120 mg/mL solution single-dose prefilled syringe or prefilled pen; Emgality® galcanezumab-gnlm 100 mg/mL solution single-dose prefilled syringe Vyepti™ eptinezumab-jjmr Intravenous (IV) solution: 100 mg/mL Indication Aimovig® (erenumab-aooe): A high-affinity human immunoglobulin G2 (IgG2) monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor, is indicated for the preventative treatment of migraine in adults. Ajovy® (fremanezumab-vfrm): A human IgG2 monoclonal antibody that targets the CGRP receptor, is indicated for the preventative treatment of migraine in adults. Emgality® (galcanezumab-gnlm): A human immunoglobulin IgG4 monoclonal antibody that targets the CGRP ligand, is indicated for the preventative treatment of migraine and episodic cluster headaches in adults. Vyepti™ (eptinezumab-jjmr): A humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets the CGRP ligand and inhibits its interaction with the receptor, is indicated for the preventative treatment of migraine in adults. Proprietary & Confidential © 2003–2021 Magellan Health, Inc. All rights reserved. Magellan Medicaid Administration, part of the Magellan Rx Management division of Magellan Health, Inc. Migraine Headache Prevention Request Criteria for Approval 1. Patient has a diagnosis of migraine with or without aura based on International Classification of Headache Disorders (ICHD-III) diagnostic criteria; AND 2.
    [Show full text]